251 related articles for article (PubMed ID: 35016723)
1. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
2. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
3. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals.
Wu S; Luo Z; Yu PJ; Xie H; He YW
Biol Chem; 2016 Jan; 397(1):75-83. PubMed ID: 26431101
[TBL] [Abstract][Full Text] [Related]
5. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.
Varešlija D; Ward E; Purcell SP; Cosgrove NS; Cocchiglia S; O'Halloran PJ; Charmsaz S; Bane FT; Brett FM; Farrell M; Cryan J; Beausang A; Hudson L; Turnbul AK; Dixon JM; Hill ADK; Priedigkeit N; Oesterreich S; Lee AV; Sims AH; Redmond AM; Carroll JS; Young LS
Oncogene; 2021 Feb; 40(7):1318-1331. PubMed ID: 33420368
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of histone deacetylase-8 in human breast cancer.
Rahmani G; Sameri S; Abbasi N; Abdi M; Najafi R
Pathol Res Pract; 2021 Apr; 220():153396. PubMed ID: 33691240
[TBL] [Abstract][Full Text] [Related]
8. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3β/Snail signals.
An P; Chen F; Li Z; Ling Y; Peng Y; Zhang H; Li J; Chen Z; Wang H
Oncogene; 2020 Jun; 39(26):4956-4969. PubMed ID: 32499521
[TBL] [Abstract][Full Text] [Related]
9. Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.
Mieczkowska IK; Pantelaiou-Prokaki G; Prokakis E; Schmidt GE; Müller-Kirschbaum LC; Werner M; Sen M; Velychko T; Jannasch K; Dullin C; Napp J; Pantel K; Wikman H; Wiese M; Kramm CM; Alves F; Wegwitz F
Cell Death Dis; 2021 Nov; 12(12):1118. PubMed ID: 34845197
[TBL] [Abstract][Full Text] [Related]
10. The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells.
Chung VY; Tan TZ; Ye J; Huang RL; Lai HC; Kappei D; Wollmann H; Guccione E; Huang RY
Commun Biol; 2019; 2():272. PubMed ID: 31372511
[TBL] [Abstract][Full Text] [Related]
11. Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition.
Chang H; Liu Y; Xue M; Liu H; Du S; Zhang L; Wang P
Nucleic Acids Res; 2016 Apr; 44(6):2514-27. PubMed ID: 26926107
[TBL] [Abstract][Full Text] [Related]
12. Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration.
Meyer-Schaller N; Heck C; Tiede S; Yilmaz M; Christofori G
Breast Cancer Res; 2018 Oct; 20(1):118. PubMed ID: 30285803
[TBL] [Abstract][Full Text] [Related]
13. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract][Full Text] [Related]
14. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.
Menbari MN; Rahimi K; Ahmadi A; Mohammadi-Yeganeh S; Elyasi A; Darvishi N; Hosseini V; Abdi M
J Cell Physiol; 2020 Mar; 235(3):2631-2642. PubMed ID: 31508813
[TBL] [Abstract][Full Text] [Related]
15. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
18. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
Oncotarget; 2017 Jan; 8(5):7489-7501. PubMed ID: 27283490
[TBL] [Abstract][Full Text] [Related]
19. Mnt Represses Epithelial Identity To Promote Epithelial-to-Mesenchymal Transition.
Lavin DP; Abassi L; Inayatullah M; Tiwari VK
Mol Cell Biol; 2021 Oct; 41(11):e0018321. PubMed ID: 34460331
[TBL] [Abstract][Full Text] [Related]
20. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
